中草药

熟地黄防治神经发育和神经退行性疾病的物质基础及其生物学机制研究进展

PDF下载

中草药 | 综述 2026,57(7): 2848-2864

收起

中草药 |综述 2026 , 57 (7) : 2848 -2864

熟地黄防治神经发育和神经退行性疾病的物质基础及其生物学机制研究进展

全屏

裴方妤¹, 吴吉², 贺思雨², 赵莎³, 张涤⁴, 李凡⁴, 雷倩⁴, 雷东方⁵, 朱沁泉⁴

作者信息

通讯作者:

雷东方

作者简介:

裴方妤: 裴方妤,硕士研究生,研究方向为中医药防治儿科疾病研究。E-mail:810937642@qq.com

Advances in material basis and biological mechanisms of Rehmanniae Radix Praeparata in prevention and treatment of neurodevelopmental and neurodegenerative diseases

PEI Fangyu, WU Ji, HE Siyu, ZHAO Sha, ZHANG Di, LI Fan, LEI Qian, LEI Dongfang, ZHU Qinquan

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.07.033

文章导航

摘要

收起

熟地黄Rehmanniae Radix Praeparata是滋养肾精、补益精髓的重要药材，应用于辨证属“肾精亏虚”相关证候的防治。现代研究发现，地黄在神经发育障碍（neurodevelopmental disorders，NDDs）及神经退行性疾病（neurodegenerative diseases，NDs）的防治中具有潜在价值。2种疾病病理机制复杂，临床均缺乏有效治疗药物，研究表明二者存在共同的神经病理机制，而传统中医认为二者关键病机为“肾精亏虚”。在综述熟地黄对NDDs及NDs治疗优势的基础上，深入剖析熟地黄通过补肾填精防治这2类疾病的潜在生物学机制，并为熟地黄在促进神经发育与干预神经退行性疾病方面的作用机制提供新见解，促进对其药效机制的深入理解及后续的药物研发。同时，也为传统中医药理论中的“补肾填精”与“异病同治”原则在神经疾病领域的实践应用提供科学依据，推动中医药现代化进程。

关键词

熟地黄 / 神经发育障碍 / 神经退行性病变 / 肾精亏虚 / 补肾填精

Abstract

收起

Shudihuang (Rehmanniae Radix Praeparata), a fundamental herb in traditional Chinese medicine, is widely used to nourish kidney essence and replenish marrow. It is commonly applied in the prevention and treatment of syndromes related to “kidney essence deficiency”. Modern research has revealed its potential therapeutic value in neurodevelopmental disorders (NDDs) and neurodegenerative diseases (NDs). Given the complex pathological mechanisms of both conditions and the current lack of effective clinical treatments, studies suggest that NDDs and NDs share common neuropathological mechanisms. Traditional Chinese medicine theory posits that “kidney essence deficiency” is a key pathological mechanism underlying both disorders. This article, while reviewing the therapeutic advantages of Rehmanniae Radix Praeparata in treating NDDs and NDs, aims to provide an in-depth analysis of its potential biological mechanisms in preventing and treating these two categories of diseases through its action of “tonifying the kidney and replenishing essence”. Furthermore, it seeks to offer new insights into the herb’s role in promoting neurodevelopment and intervening in neurodegenerative processes, thereby fostering a deeper understanding of its pharmacological mechanisms and supporting subsequent drug development. This study also provides scientific evidence for the application of the TCM principles of “tonifying the kidney and replenishing essence” and “treating different diseases with the same method” in the field of neurological disorders, contributing to the modernization of traditional Chinese medicine.

Key words

Rehmanniae Radix Praeparata / neurodevelopmental disorders / neurodegenerative diseases / kidney essence deficiency / tonifying kidney and replenishing essence

引用本文

裴方妤, 吴吉, 贺思雨, 赵莎, 张涤, 李凡, 雷倩, 雷东方, 朱沁泉. 熟地黄防治神经发育和神经退行性疾病的物质基础及其生物学机制研究进展. 中草药, 2026 , 57 (7) : 2848 -2864 . DOI: 10.7501/j.issn.0253-2670.2026.07.033

PEI Fangyu, WU Ji, HE Siyu, ZHAO Sha, ZHANG Di, LI Fan, LEI Qian, LEI Dongfang, ZHU Qinquan. Advances in material basis and biological mechanisms of Rehmanniae Radix Praeparata in prevention and treatment of neurodevelopmental and neurodegenerative diseases[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (7) : 2848 -2864 . DOI: 10.7501/j.issn.0253-2670.2026.07.033

基金

收起

湖南省自然科学基金 (2024JJ8233); 湖南省中医药科研计划 (A2023036); 湖南省卫生健康高层次人才项目 (20230448); 2024年湖南省大学生创新创业训练计划 (S202410541157); 湖南中医药大学校级创新课题 (2025XYLH038)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Lukens J R, Eyo U B. Microglia and neurodevelopmental disorders[J]. Annu Rev Neurosci, 2022, 45:425-445.
Agnello L, Ciaccio M. Neurodegenerative diseases:From molecular basis to therapy[J]. Int J Mol Sci, 2022, 23(21):12854.
Temple S. Advancing cell therapy for neurodegenerative diseases[J]. Cell Stem Cell, 2023, 30(5):512-529.
Malar D S, Thitilertdecha P, Ruckvongacheep K S, et al.Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders[J].CNS Drugs, 2023, 37(5):399-440.
陈自佳,韩枝彤,王素梅.王素梅从肾脑论治孤独症谱系障碍临床经验[J].北京中医药, 2023, 42(6):648-650.
张登峰,王泰愚,王响,等.地黄的临床应用及其用量探究[J].辽宁中医杂志, 2024, 51(9):23-26.
高如汐,王凡一,刘想,等.熟地黄历史沿革及其化学成分和药理作用研究进展[J].辽宁中医药大学学报,2025, 27(5):167-176.
赵婧含,李雪,吴文轩,等.熟地黄的化学成分及药理作用研究进展[J].中医药学报, 2023, 51(6):110-114.
Jia J H, Chen J F, Wang G L, et al. Progress of research into the pharmacological effect and clinical application of the traditional Chinese medicine Rehmanniae Radix[J].Biomed Pharmacother, 2023, 168:115809.
葛楠,闫广利,孙晖,等.熟地黄药效物质基础研究进展[J].中草药, 2023, 54(1):292-302.
赵婧含,李雪,吴文轩,等.生地黄提取物及其有效成分的药理作用研究进展[J].药物评价研究, 2024,47(10):2443-2448.
Jiang B, Shen R F, Bi J, et al. Catalpol:A potential therapeutic for neurodegenerative diseases[J]. Curr Med Chem, 2015, 22(10):1278-1291.
刘娟娟,吕锦锦,张靖柯,等.九蒸九晒熟地黄化学成分研究[J].中国药学杂志, 2021, 56(6):449-456.
Nadeem M S, Hosawi S, Alshehri S, et al. Symptomatic,genetic, and mechanistic overlaps between autism and Alzheimer’s disease[J]. Biomolecules, 2021, 11(11):1635.
Khan S A, Khan S A, Narendra A R, et al. Alzheimer’s disease and autistic spectrum disorder:Is there any association?[J]. CNS Neurol Disord Drug Targets, 2016,15(4):390-402.
Martinez S, Stoyanov K, Carcache L. Unraveling the spectrum:Overlap, distinctions, and nuances of ADHD and ASD in children[J]. Front Psychiatry, 2024, 15:1387179.
Hanamsagar R, Bilbo S D. Sex differences in neurodevelopmental and neurodegenerative disorders:Focus on microglial function and neuroinflammation during development[J]. J Steroid Biochem Mol Biol, 2016,160:127-133.
Mishra A, Bandopadhyay R, Singh P K, et al.Neuroinflammation in neurological disorders:Pharmacotherapeutic targets from bench to bedside[J].Metab Brain Dis, 2021, 36(7):1591-1626.
Farrag E A E, Askar M H, Abdallah Z, et al. Comparative effect of atorvastatin and risperidone on modulation of TLR4/NF-κB/NOX-2 in a rat model of valproic acidinduced autism[J]. Behav Brain Funct, 2024, 20(1):26.
McManus R M, Latz E. NLRP3 inflammasome signalling in Alzheimer’s disease[J]. Neuropharmacology, 2024,252:109941.
Liu T W, Chen C M, Chang K H. Biomarker of neuroinflammation in Parkinson’s disease[J]. Int J Mol Sci, 2022, 23(8):4148.
Uygun S D, Kose T B, Bahadir-Varol A, et al. Attentionrelated impairment and contributing neuroinflammatory signalling in the prefrontal cortex of perinatal nicotineexposed mice[J]. Acta Neuropsychiatr, 2025, 37:e12.
Zhao K Y, Liu J H, Sun T, et al. The miR-25802/KLF4/NF-κB signaling axis regulates microglia-mediated neuroinflammation in Alzheimer’s disease[J]. Brain Behav Immun, 2024, 118:31-48.
Alnakhli A M, Saleh A, Kabel A M, et al. Perindopril ameliorates sodium valproate-induced rat model of autism:Involvement of sirtuin-1, JAK2/STAT3 axis, PI3K/Akt/GSK-3β pathway, and PPAR-gamma signaling[J].Medicina, 2024, 60(11):1802.
Panda S P, Kesharwani A, Datta S, et al. JAK2/STAT3 as a new potential target to manage neurodegenerative diseases:An interactive review[J]. Eur J Pharmacol,2024, 970:176490.
Wang L, Yang Z Y, He X M, et al. Mitochondrial protein dysfunction in pathogenesis of neurological diseases[J].Front Mol Neurosci, 2022, 15:974480.
Kalra J. Crosslink between mutations in mitochondrial genes and brain disorders:Implications for mitochondrialtargeted therapeutic interventions[J]. Neural Regen Res,2023, 18(1):94-101.
Wang J, Rappold G A, Fröhlich H. Disrupted mitochondrial network drives deficits of learning and memory in a mouse model of FOXP1 haploinsufficiency[J]. Genes, 2022, 13(1):127.
Verma H, Gangwar P, Yadav A, et al. Understanding the neuronal synapse and challenges associated with the mitochondrial dysfunction in mild cognitive impairment and Alzheimer’s disease[J]. Mitochondrion, 2023, 73:19-29.
Choong C J, Mochizuki H. Involvement of mitochondria in Parkinson’s disease[J]. Int J Mol Sci, 2023, 24(23):17027.
Zhang T, Sun Y N, Wei J, et al. Shorter telomere length in children with autism spectrum disorder is associated with oxidative stress[J]. Front Psychiatry, 2023, 14:1209638.
Alqahtani T, Deore S L, Kide A A, et al. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease,and Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis-An updated review[J].Mitochondrion, 2023, 71:83-92.
Banerjee R, Mukherjee A, Nagotu S. Mitochondrial dynamics and its impact on human health and diseases:Inside the DRP1 blackbox[J]. J Mol Med, 2022, 100(1):1-21.
Dhapola R, Sarma P, Medhi B, et al. Recent advances in molecular pathways and therapeutic implications targeting mitochondrial dysfunction for Alzheimer’s disease[J].Mol Neurobiol, 2022, 59(1):535-555.
Eldeeb M A, Thomas R A, Ragheb M A, et al.Mitochondrial quality control in health and in Parkinson’s disease[J]. Physiol Rev, 2022, 102(4):1721-1755.
Czabotar P E, Garcia-Saez A J. Mechanisms of BCL-2family proteins in mitochondrial apoptosis[J]. Nat Rev Mol Cell Biol, 2023, 24(10):732-748.
Rahman S, Copeland W C. POLG-related disorders and their neurological manifestations[J]. Nat Rev Neurol,2019, 15(1):40-52.
Abu Shelbayeh O, Arroum T, Morris S, et al. PGC-1α is a master regulator of mitochondrial lifecycle and ROS stress response[J]. Antioxidants, 2023, 12(5):1075.
Li J, Yang D M, Li Z P, et al. PINK1/Parkin-mediated mitophagy in neurodegenerative diseases[J]. Ageing Res Rev, 2023, 84:101817.
Ghatak S, Talantova M, McKercher S R, et al. Novel therapeutic approach for excitatory/inhibitory imbalance in neurodevelopmental and neurodegenerative diseases[J]. Annu Rev Pharmacol Toxicol, 2021, 61:701-721.
Mony L, Paoletti P. Mechanisms of NMDA receptor regulation[J]. Curr Opin Neurobiol, 2023, 83:102815.
Puranik N, Song M. Glutamate:Molecular mechanisms and signaling pathway in Alzheimer’s disease, a potential therapeutic target[J]. Molecules, 2024, 29(23):5744.
Havranek T, Bacova Z, Bakos J. Oxytocin, GABA, and dopamine interplay in autism[J]. Endocr Regul, 2024,58(1):105-114.
Wang Y R, Xu H, Chen S Y, et al. Oxytocin protects nigrostriatal dopamine signal via activating GABAergic circuit in the MPTP-induced Parkinson’s disease model[J]. Adv Sci, 2024, 11(36):2310244.
Zhao X Y, Hu Q G, Wang X Q, et al. Dual-target inhibitors based on acetylcholinesterase:Novel agents for Alzheimer’s disease[J]. Eur J Med Chem, 2024, 279:116810.
Gallo E F, Greenwald J, Yeisley J, et al. Dopamine D2receptors modulate the cholinergic pause and inhibitory learning[J]. Mol Psychiatry, 2022, 27(3):1502-1514.
Sato M, Nakai N, Fujima S, et al. Social circuits and their dysfunction in autism spectrum disorder[J]. Mol Psychiatry, 2023, 28(8):3194-3206.
Zhou Z D, Yi L X, Wang D Q, et al. Role of dopamine in the pathophysiology of Parkinson’s disease[J]. Transl Neurodegener, 2023, 12(1):44.
Fischer I, Shohat S, Leichtmann-Bardoogo Y, et al. Shank3mutation impairs glutamate signaling and myelination in ASD mouse model and human iPSC-derived OPCs[J]. Sci Adv, 2024, 10(41):eadl4573.
Andersen J V, Schousboe A, Verkhratsky A. Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease:Integration of the glutamate/GABA-glutamine cycle[J]. Prog Neurobiol, 2022, 217:102331.
Tosta A, Fonseca A S, Messeder D, et al. Effects of gestational exercise on nociception, BDNF, and irisin levels in an animal model of ADHD[J]. Neuroscience,2024, 543:37-48.
Rahman M M, Islam M R, Supti F A, et al. Exploring the therapeutic effect of neurotrophins and neuropeptides in neurodegenerative diseases:At a glance[J]. Mol Neurobiol, 2023, 60(8):4206-4231.
Khoodoruth M A S, Chut-Kai Khoodoruth W N, Al Alwani R. Exploring the epigenetic landscape:The role of 5-hydroxymethylcytosine in neurodevelopmental disorders[J]. Camb Prism Precis Med, 2024, 2:e5.
Stoccoro A, Conti E, Scaffei E, et al. DNA methylation biomarkers for young children with idiopathic autism spectrum disorder:A systematic review[J]. Int J Mol Sci,2023, 24(11):9138.
Masini E, Loi E, Vega-Benedetti A F, et al. An overview of the main genetic, epigenetic and environmental factors involved in autism spectrum disorder focusing on synaptic activity[J]. Int J Mol Sci, 2020, 21(21):8290.
Dadds M R, Schollar-Root O, Lenroot R, et al. Epigenetic regulation of the DRD4 gene and dimensions of attentiondeficit/hyperactivity disorder in children[J]. Eur Child Adolesc Psychiatry, 2016, 25(10):1081-1089.
Prasanth M I, Sivamaruthi B S, Cheong C S Y, et al. Role of epigenetic modulation in neurodegenerative diseases:Implications of phytochemical interventions[J].Antioxidants, 2024, 13(5):606.
De Plano L M, Saitta A, Oddo S, et al. Epigenetic changes in Alzheimer’s disease:DNA methylation and histone modification[J]. Cells, 2024, 13(8):719.
Zhang J N, Li Q, Yang F. Role of epigenetic modifications in Parkinson’s disease[J]. Epigenomics, 2023, 15(10):573-576.
Tseng C J, McDougle C J, Hooker J M, et al. Epigenetics of autism spectrum disorder:Histone deacetylases[J]. Biol Psychiatry, 2022, 91(11):922-933.
Mondal P, Bai P, Gomm A, et al. Structure-based discovery of a small molecule inhibitor of histone deacetylase 6(HDAC6)that significantly reduces Alzheimer’s disease neuropathology[J]. Adv Sci, 2024, 11(1):2304545.
Kouakou M R, Cameron D, Hannon E, et al. Sites of active gene regulation in the prenatal frontal cortex and their role in neuropsychiatric disorders[J]. Am J Med Genet B Neuropsychiatr Genet, 2021, 186(6):376-388.
Fisher R M A, Torrente M P. Histone post-translational modification and heterochromatin alterations in neurodegeneration:Revealing novel disease pathways and potential therapeutics[J]. Front Mol Neurosci, 2024, 17:1456052.
Yan Z. Targeting epigenetic enzymes for autism treatment[J]. Trends Pharmacol Sci, 2024, 45(9):764-767.
Williams J B, Cao Q, Wang W, et al. Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model[J]. Nat Commun,2023, 14(1):91.
赵婧含,李雪,吴文轩,等.熟地黄的化学成分及药理作用研究进展[J].中医药学报, 2023, 51(6):110-114.
王清泉,宋景,李亚男,等.地黄多糖的提取纯化及药理作用研究进展[J].中草药, 2023, 54(11):3734-3744.
马媛媛,姚晓英,谈卓臣,等.地黄多糖对东莨菪碱诱导小鼠学习记忆能力障碍的改善作用及其机制[J].中成药, 2021, 43(6):1462-1466.
卢雨菲,闵清.环烯醚萜苷的提取工艺及药理作用研究进展[J].湖北科技学院学报:医学版, 2025, 39(4):358-362.
陈慧泽,邓楚珺,孟泽宇,等.梓醇-川芎嗪方调控STAT3改善阿尔茨海默病神经可塑性的机制研究[J].中西医结合心脑血管病杂志, 2024, 22(21):3899-3906.
Zhang B X, Zhou N, Zhang Z K, et al. Study on the neuroprotective effects of eight iridoid components using cell metabolomics[J]. Molecules, 2024, 29(7):1497.
张莉,卢仁睿,王慧慧,等.地黄苷D对皮质酮诱导的PC-12细胞损伤的保护作用及机制研究[J].中草药,2022, 53(11):3385-3393.
王慧慧,卢仁睿,张莉,等.地黄中地黄苷D通过调控小胶质细胞M1/M2极化抑制神经炎症[J].中药材,2021, 44(11):2683-2687.
Xiao Y S, Ren Q, Wu L H. The pharmacokinetic property and pharmacological activity of acteoside:A review[J].Biomed Pharmacother, 2022, 153:113296.
谢良骐,柴智,弓强,等.毛蕊花糖苷对中枢神经系统的作用及其机制研究进展[J].中华中医药学刊, 2024,42(7):179-182.
曾昕,罗飞.毛蕊花糖苷对阿尔茨海默病小鼠神经炎性反应及对ERK1/2-Nrf2通路的影响[J].吉林医学,2024, 45(1):1-4.
张明洋,杨新玲.毛蕊花糖苷对MPTP制备的帕金森病模型小鼠的神经保护作用及机制研究[J].神经疾病与精神卫生, 2024, 24(5):364-370.
周志华,邢海燕,梁彦,等.毛蕊花糖苷促进神经递质乙酰胆碱释放的分子机制[J].中国中药杂志, 2025,50(2):335-345.
杨扬,万凤,侯晓梦,等.熟地黄中促神经干细胞增殖活性的成分研究[J].中南药学, 2024, 22(5):1201-1206.
Li J, Yu H N, Yang C, et al. Therapeutic potential and molecular mechanisms of echinacoside in neurodegenerative diseases[J]. Front Pharmacol, 2022,13:841110.
朱红敏,袁纯辉.儿童神经发育障碍疾病研究进展[J].中国当代儿科杂志, 2023, 25(1):91-97.
袁海霞,倪新强,吴正治,等.基于“肾脑相关”研究熟地黄对ADHD模型SHR大鼠前额叶、纹状体BDNF/TrkB及NRG-3的调控作用[J].中国中药杂志, 2018,43(17):3539-3544.
Sun R X, Yuan H X, Wang J, et al. Rehmanniae Radix Preparata ameliorates behavioral deficits and hippocampal neurodevelopmental abnormalities in ADHD rat model[J]. Front Neurosci, 2024, 18:1402056.
王静,倪新强,李利民,等.基于“阴静阳躁”理论探讨熟地黄对注意缺陷多动障碍大鼠前额叶皮质能量代谢的影响[J].中国中药杂志, 2022, 47(13):3554-3561.
Yuan H X, Ni X Q, Zheng M, et al. Effect of catalpol on behavior and neurodevelopment in an ADHD rat model[J]. Biomed Pharmacother, 2019, 118:109033.
Su Y F, Liu N N, Sun R Q, et al. Radix Rehmanniae Praeparata(Shu Dihuang)exerts neuroprotective effects on ICV-STZ-induced Alzheimer’s disease mice through modulation of INSR/IRS-1/AKT/GSK-3β signaling pathway and intestinal microbiota[J]. Front Pharmacol,2023, 14:1115387.
Tian L Y, Li H W, Xiong W, et al. Proteomic alteration in catalpol treatment of Alzheimer’s disease by regulating HSPA5/GPX4[J]. Eur J Pharmacol, 2025, 987:177075.
Du J K, Liu J R, Huang X M, et al. Catalpol ameliorates neurotoxicity in N2a/APP695swe cells and APP/PS1transgenic mice[J]. Neurotox Res, 2022, 40(4):961-972.
Chen Y J, Yu Y. Tau and neuroinflammation in Alzheimer’s disease:Interplay mechanisms and clinical translation[J].J Neuroinflammation, 2023, 20(1):165.
Li S, Tian Z Q, Xian X H, et al. Catalpol rescues cognitive deficits by attenuating amyloid β plaques and neuroinflammation[J]. Biomed Pharmacother, 2023, 165:115026.
Liu C Y, Chen K, Lu Y W, et al. Catalpol provides a protective effect on fibrillary Aβ(1-42)-induced barrier disruption in an in vitro model of the blood-brain barrier[J]. Phytother Res, 2018, 32(6):1047-1055.
Wang Z, Huang X S, Zhao P, et al. Catalpol inhibits amyloid-β generation through promoting α-cleavage of APP in Swedish mutant APP overexpressed N2a cells[J].Front Aging Neurosci, 2018, 10:66.
Xiang C X, Lu Y W, Hao R J, et al. Catalpol alleviates amyloid-generation and neuronal oxidative stress injury via activating the Keap1-Nrf2/ARE signaling pathway in the immortalized lymphocytes from patients with lateonset Alzheimer’s disease and SKNMC cells co-culture model[J]. Iran J Basic Med Sci, 2024, 27(12):1547-1557.
Meng S X, Chen H Z, Deng C J, et al. Catalpol mitigates Alzheimer’s disease progression by promoting the expression of neural stem cell exosomes released miR-138-5p[J]. Neurotox Res, 2023, 41(1):41-56.
Chen S S, Liu H H, Wang S M, et al. The neuroprotection of verbascoside in Alzheimer’s disease mediated through mitigation of neuroinflammation via blocking NF-κB-p65signaling[J]. Nutrients, 2022, 14(7):1417.
Wang C Y, Cai X Y, Wang R C, et al. Neuroprotective effects of verbascoside against Alzheimer’s disease via the relief of endoplasmic reticulum stress in Aβ-exposed U251cells and APP/PS1 mice[J]. J Neuroinflammation, 2020,17(1):309.
Dai Y, Han G H, Xu S J, et al. Echinacoside suppresses amyloidogenesis and modulates F-actin remodeling by targeting the ER stress sensor PERK in a mouse model of Alzheimer’s disease[J]. Front Cell Dev Biol, 2020, 8:593659.
Qiu H, Liu X M. Echinacoside improves cognitive impairment by inhibiting Aβ deposition through the PI3K/AKT/Nrf2/PPARγ signaling pathways in APP/PS1mice[J]. Mol Neurobiol, 2022, 59(8):4987-4999.
Castillo-Rangel C, Marin G, Hernández-Contreras K A, et al. Neuroinflammation in Parkinson’s disease:From gene to clinic:A systematic review[J]. Int J Mol Sci, 2023,24(6):5792.
Wang L Y, Yu X, Li X X, et al. Catalpol exerts a neuroprotective effect in the MPTP mouse model of Parkinson’s disease[J]. Front Aging Neurosci, 2019, 11:316.
Li M Q, Zhou F, Xu T, et al. Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway[J]. Food Chem Toxicol, 2018,119:6-13.
Zhao Y, Wang S J, Pan J, et al. Verbascoside:A neuroprotective phenylethanoid glycosides with antidepressive properties[J]. Phytomedicine, 2023, 120:155027.
Han Z, Wang B, Wen Y Q, et al. Acteoside alleviates lipid peroxidation by enhancing Nrf2-mediated mitophagy to inhibit ferroptosis for neuroprotection in Parkinson’s disease[J]. Free Radic Biol Med, 2024, 223:493-505.
Aimaiti M, Wumaier A, Aisa Y, et al. Acteoside exerts neuroprotection effects in the model of Parkinson’s disease via inducing autophagy:Network pharmacology and experimental study[J]. Eur J Pharmacol, 2021, 903:174136.
Gao M R, Wang M, Jia Y Y, et al. Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson’s disease model[J]. Brain Res Bull, 2020, 164:55-64.
Yang X P, Huang J H, Ye F L, et al. Echinacoside exerts neuroprotection via suppressing microglial α-synuclein/TLR2/NF-κB/NLRP3 axis in Parkinsonian models[J]. Phytomedicine, 2024, 123:155230.
Liang Y, Chen C, Xia B M, et al. Neuroprotective effect of echinacoside in subacute mouse model of Parkinson’s disease[J]. Biomed Res Int, 2019, 2019:4379639.
Wang Y H, Xuan Z H, Tian S, et al. Echinacoside protects against 6-hydroxydopamine-induced mitochondrial dysfunction and inflammatory responses in PC12 cells via reducing ROS production[J]. Evid Based Complement Alternat Med, 2015, 2015:189239.
Geng X, Zou Y H, Li J H, et al. BDNF alleviates Parkinson’s disease by promoting STAT3 phosphorylation and regulating neuronal autophagy[J]. Cell Tissue Res,2023, 393(3):455-470.
Yang X P, Yv Q, Ye F L, et al. Echinacoside protects dopaminergic neurons through regulating IL-6/JAK2/STAT3 pathway in Parkinson’s disease model[J].Front Pharmacol, 2022, 13:848813.
罗刘军,祝美珍,陈兰,等.基于“肾-脑髓-干细胞”轴探讨缺血性卒中及神经再生[J].辽宁中医药大学学报, 2020, 22(3):104-107.
高歌.熟地黄促衰老神经干细胞增殖的药效物质基础研究[D].北京:北京中医药大学, 2020.
王重一,邓洋洋,高巳东,等.试论肾藏精主骨为先天之本与表观遗传学的关系[J].中国中医药现代远程教育, 2023, 21(7):56-58.
张辉,王红艳,彭思涵,等.金匮肾气丸防治PTSD孕鼠胎损的表观遗传机制:Ntf3高甲基化[J].中华中医药杂志, 2016, 31(11):4499-4501
刘宁,韩诚,贺文彬,等.基于m-6A甲基化修饰调控突触可塑性探究地黄饮子对阿尔茨海默病认知功能的影响[J].中华中医药杂志, 2024, 39(11):6191-6195.
王凯,昝树杰,徐家淳,等.中医“脑髓”的现代生物学基础探讨[J].中华中医药杂志, 2024, 39(2):566-570.
梁建庆,何建成.复方地黄颗粒对阴虚动风证帕金森病模型大鼠神经营养因子及其受体的影响[J].解放军医学杂志, 2018, 43(8):647-651.
康湘萍,梁超,金国琴,等. p75 NTR介导神经细胞凋亡对老龄鼠学习记忆的影响及补肾方药的作用[J].中国老年学杂志, 2015, 35(15):4117-4120.
盛望,李旭华,胡国恒,等.肾脑复元汤对阿尔茨海默病模型大鼠学习记忆及凋亡相关蛋白的影响[J].世界中西医结合杂志, 2017, 12(8):1072-1076.
王静,朱康琳,倪新强,等.基于Bcl-2/Bax/caspase-3通路探讨熟地黄对注意缺陷多动障碍大鼠纹状体神经元凋亡的影响[J].中国中药杂志, 2025, 50(3):750-757.
李龙宣,赵斌,许志恩,等.熟地黄抑制阿尔茨海默病样大鼠海马神经元凋亡的作用[J].中华神经医学杂志, 2006, 5(1):10-13.
李林,魏海峰,张兰,等.中医“肾生髓,脑为髓海”现代生物学基础探讨[J].中国中药杂志, 2006, 31(17):1397-1400.
李潇清. NLRP3介导补肾益髓法调节帕金森病小鼠神经炎症的研究[D].北京:北京中医药大学, 2021.
易健.从小胶质细胞活化探讨六味地黄汤对Aβ损伤神经元的保护机制[D].长沙:湖南中医药大学, 2018.
王学美,富宏,刘庚信.肾虚衰老与线粒体DNA氧化损伤关系的研究[J].中医杂志, 2002, 43(4):294-295.
吉晓晓,马宁,崔霞,等.基于线粒体能量代谢障碍从脾肾-脑论治儿童孤独症谱系障碍[J].湖南中医药大学学报, 2025, 45(3):486-490.
王孟菲,高卫平,袁永,等.基于线粒体-内质网偶联结构探讨从肾论治阿尔茨海默病的科学内涵[J].世界中医药, 2024, 19(24):3855-3859.
朱超,张正,朱友松,等.基于“肾脑相济”理论与线粒体稳态相关性探讨补肾方药治疗阿尔茨海默病的机制[J].山西中医药大学学报, 2024, 25(7):806-810.
王小雅,王琪,范淑华.多巴丝肼片联合复方地黄汤治疗帕金森病的疗效及对患者神经递质水平的影响[J].内科, 2021, 16(6):795-797.
王玉洁,张驰骋,刘钰淇,等.地黄饮子联合西药治疗帕金森病临床疗效的Meta分析[J].现代中药研究与实践, 2025, 39(1):78-84.
张彤,安红梅,张立敏.地黄益智方保护H2O2诱导的PC12细胞损伤的作用机制[J].中医药学报, 2025,53(1):20-28.
侯文晓,司蕊豪,刘羽茜,等.六味地黄丸通过FcγRIIB/c-Src通路干预自噬防治阿尔茨海默病的分子机制[J].世界科学技术-中医药现代化, 2025, 27(3):724-738.
江建锋,白强,宋祯彦,等.从凋亡网络的调控研究地黄饮子治疗阿尔兹海默病的分子机制[J].中草药,2020, 51(21):5548-5558.
杨晶,王世界,郝莉,等.六味地黄丸对老龄小鼠海马突触可塑性的作用[J].中成药, 2023, 45(4):1093-1100.
吴吉,郝兴宇,叶勇,等.基于BDNF/TrkB/CREB通路研究六味地黄丸对丙戊酸钠诱导的孤独症谱系障碍模型仔鼠的作用机制[J].湖南中医药大学学报, 2024,44(2):176-184.

2026年第57卷第7期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.07.033

接收时间：2025-09-21
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-09-21

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.07.033

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT